Fintel reports that on August 1, 2025, HC Wainwright & Co. downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Zynex (NASDAQ:ZYXI), a medical technology company specializing in non-opioid pain management devices, issued its second quarter 2025 results on July 31, 2025. The release highligh ...

Zynex (ZYXI) delivered earnings and revenue surprises of -60.00% and -17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Q2 2025 Earnings Call Transcript July 31, 2025 Zynex, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.13. Operator: Good afternoon, ladies and gentlemen, and ...

Zynex, Inc. reports Q2 2025 earnings with a $40M cost-reduction plan, leadership transitions, and FDA progress on its NiCO pulse oximeter.

Zynex Inc (NASDAQ:ZYXI) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $27.38 million, and the earnings are expected to come in at -$0.20 per ...

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of ...

An announcement from Zynex ( (ZYXI) ) is now available.

Zynex Chief Financial Officer Dan Moorhead is resigning. Moorhead plans to leave Aug. 29 and the move isn't the result of a disagreement with the company, the medical device maker said Tuesday.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient ...

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...